ESMO IO 2021 – Mark G. Kris
Mark G. Kris outlines the potential of circulating tumor DNA along the neoadjuvant cancer treatment timeline, explains which correlations have been observed between changes in ctDNA levels and clinical outcomes in patients with early-stage lung cancer and how monitoring of ctDNA can potentially be utilized in clinical practice to guide the management of these patients, while also depicting the limitations of this approach. The excitement in the field of lung cancer about new drugs targeting KRAS in combination with immunotherapy for first line treatment in stage IV NSCLC is addressed, too.
Here is the full ESMO IO 2021 report.
More posts
Immune checkpoint blockade combined with chemotherapy in solid tumors
Non-small cell lung cancer (NSCLC) is a severe disease with poor outcomes since the majority of patients present with stage IV disease at diagnosis. Approved treatment options in the first-line setting of advanced NSCLC (aNSCLC) with wildtype EGFR/ALK include bevacizumab - a VEGF targeting monoclonal antibody - and PD-1/PD-L1 inhibitors in combination with chemotherapy.
Preface
The ESMO Immuno-Oncology Congress 2021 took place as a hybrid event either in Geneva or online from 8th to 11th December 2021. Compared with the annual ESMO scientific congress, this meeting focused exclusively on the most exciting new data in the promising field of immuno-oncology. In total, 1,124 participants from 67 countries attended one of the 31 on-demand sessions featuring over 193 abstracts, 178 e-posters, 146 presentations and 20 educational sessions.
